HK2 is overexpressed in a variety of tumor cells, and studies have shown that HK2 ablation delays lung and breast tumor progression [47], while HK2 silencing reinstates the flux of pyruvate to the TCA cycle and suppresses aerobic glycolysis, contributing to tumor therapy [48]. This evidence concerns the gene HK2 and breast neoplasm.